07:00 , Apr 27, 2009 |  BC Week In Review  |  Company News

Immuron, Hadassah Medical Organization deal

Immuron (formerly Anadis Ltd. ) will acquire Hadassah's IP covering an oral immune modulation technology. Immuron initially will use the technology with its dairy-derived antibody technology to develop medical foods to treat metabolic syndrome and...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Clinical News

Anadis preclinical data

In an animal model of influenza, Anadis' nasal spray formulation of polyclonal antibodies reduced the likelihood and severity of influenza infection. The spray inhibited virus replication in the respiratory tract lining. Anadis Ltd. (ASX:ANX), Campbellfield,...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Anadis, Hadassah Medical Organization deal

ANX and the organization's Hadasit Medical Research Services & Development Ltd. unit will form a JV called Immuron Inc. to develop therapeutics for inflammatory and infectious diseases and cancers. Hadasit will contribute IP covering oral...
07:00 , Aug 13, 2007 |  BC Week In Review  |  Company News

Anadis, ImmuCell deal

ANX and veterinary company ICCC signed an exclusive, royalty-bearing cross-license related to their polyclonal antibody technologies. ANX will receive rights to ICCC's OTC Nisin antimicrobial peptide and Milk Immunoglobulin antibody-production technology to treat enteric and...
07:00 , Jun 4, 2007 |  BC Week In Review  |  Company News

Anadis, Australian National Security Science and Technology Unit, Emergency Management Australia other, antibodies news

ANX received a A$480,000 (US$395,000) grant from the two Australian federal government organizations to fund the early development of Project Ectoplasm, an antibody-based gel for biohazard detection, containment and decontamination. The gel would be used...